To determine the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs), and to explore contributing factors to preventable ADRs. Results were compared with vitamin K antagonists (VKAs).
Introduction
For many years vitamin K antagonists (VKA) have been the single therapy option for oral anticoagulation. Their efficacy is well established for several indications. For instance, warfarin use decreases the risk of stroke by 64% in atrial fibrillation [1] . Nevertheless, VKAs are amongst the most frequent drugs associated with adverse drug reactions (ADR) in inpatient as well as in outpatient settings [2] [3] [4] [5] . Bleedings are the main ADRs experienced by VKA-treated patients, contributing to the large underuse of oral anticoagulants (around 50% in older people) [6] .
Direct oral anticoagulants (DOACs) were developed in response to the need for oral anticoagulants that are more convenient for clinicians and patients. Four DOACs are currently used in clinical practice: three direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) and one direct thrombin inhibitor (dabigatran etexilate). They present several advantages compared with VKAs: predictable dose responses, fewer interactions with medications and food, no need for frequent laboratory monitoring, and a lower risk of intracranial bleeding [7, 8] .
However, serious ADRs have been extensively reported for patients taking DOACs, including thrombotic and bleeding events [9] [10] [11] [12] . In 2013-2014, rivaroxaban and dabigatran etexilate were among the top ten drugs implicated in emergency department admissions in older patients in the United States [13] . More importantly, previous studies revealed that some of these ADRs may be caused by medication errors [14, 15] . This suggests that ensuring safe use of DOACs in clinical practice remains a challenge.
In this prospective study, we assessed the preventability of serious ADRs related to the use of DOACs and compared results with VKAs. Furthermore, to our knowledge, the underlying causes of medication errors with oral anticoagulants have not been specifically explored using qualitative research approaches, neither for DOACs nor VKAs. Therefore, a second objective was to get a better understanding of contributing factors to preventable ADRs associated with the use of oral anticoagulants.
Methods

Setting and participants
We conducted a prospective observational cohort study on patients admitted between July 2015 and January 2016 in two teaching hospitals in Belgium (a 1000-bed hospital in an urban setting and a 450-bed hospital in a rural area). Patients aged ≥18 years, taking DOAC or VKA and presenting at the emergency department (ED) with a thromboembolic or a bleeding event were eligible for inclusion. Patients already discharged at the time of identification were excluded from the study. Thromboembolic events included ischaemic stroke, transient ischaemic attack (TIA), systemic embolism, deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients admitted with anaemia and suspected digestive haemorrhage were also included if additional investigations were carried out. The study was approved by the Ethics Committees of the Cliniques Universitaires Saint-Luc (Brussels, Belgium) and the CHU UCL Namur (Yvoir, Belgium). Written informed consent was obtained from each patient. The study was registered with clinicaltrials.gov (NCT02720328).
Data collection
Patients were identified within 24 h of their admission to the ED (72 h at the weekend). Every morning, the list of patients admitted to the ED the day before was screened for thromboembolic or bleeding events. Charts were reviewed to identify patients treated with an oral anticoagulant. We also asked ED physicians to inform the investigators when one of their patients met inclusion criteria. A clinical pharmacist (A.-L.S. or A.-S.L.) then performed a comprehensive medication history with patients (and/or relatives). A standardized form was used to collect sociodemographic, medical and medication data, along with information about anticoagulation, adverse events, drug management and adherence. Electronic medical records were also reviewed. When necessary, the general practitioner (GP), the pharmacist or relatives were contacted to gather supplementary information. In July 2016, patients' charts were examined and patients contacted by phone if needed to assess 3-month mortality.
Outcome measurements
The primary outcome was the proportion of serious adverse drug reactions (ADRs) related to the use of DOAC or VKA that were potentially preventable. According to the European Medicines Agency definitions, we considered ADR as 'a response to a medicinal product which is noxious and unintended' and we defined a serious ADR as an event that 'results in death, is life-threatening, requires in-patient hospitalization or results in persistent or significant disability or incapacity' [16] . ADRs resulting from medication errors were deemed preventable.
Secondary outcomes included analysis of anticoagulant prescribing, stages of medication process at which medication errors occurred, contribution of ADRs to hospital admission, duration of hospitalization and 3-month mortality. Factors contributing to preventable ADRs were analysed using a qualitative approach.
Analysis of anticoagulant prescribing
The Medication Appropriateness Index (MAI) was used for an in-depth analysis of DOAC and VKA prescriptions at the time of admission. This tool was developed to assess prescribing in older patients according to 10 criteria (indication, choice, dosage, administration [modalities and practicability], drugdrug interaction, drug-disease interaction, duplication, duration, cost-effectiveness) [17] . Explicit instructions were given for each criterion, defining what is considered appropriate [A], moderately appropriate [B] or inappropriate [C] . We updated a form previously developed in a pilot study to assess DOAC prescribing [18] (Appendix S1). A new form was designed to analyse VKA prescription, based on summary of product characteristics, literature review and guidelines (Appendix S1). The MAI criterion of costeffectiveness was not included. Members of a multidisciplinary team working in the field of thrombosis and haemostasis reviewed instructions of both tools. Two pharmacists (A.-L.S. and A.S.) applied independently the new form on the first ten VKA-treated patients included in the study. They discussed disagreements and the tool was improved accordingly.
Characteristics of adverse events
Two pharmacists (A.-L.S. and A.-S.L.) and two clinical haematologists (B.D. and V.M.) evaluated independently causality, seriousness and preventability of adverse events, using pilot-tested tools. For each patient, a summary of the clinical case was sent alternately to three of the four reviewers. Adverse events without an absolute agreement were discussed once a month with all reviewers. For bleeding events, causality (i.e., likelihood that a medication is the cause of an observed adverse event) was assessed using the Naranjo ADR probability scale [19] . The relationship between an inadequate therapy and a thromboembolic event was evaluated using the Therapeutic Failure Questionnaire [20] . Possible, probable and certain adverse events were considered as ADRs. Serious ADRs were then classified into unavoidable, potentially preventable and preventable ADRs using Hallas criteria [21] . For (potentially) preventable ADRs, we identified stages of medication process at which medication errors occurred (i.e., prescribing, transcribing [copying medication orders before sending them to the pharmacy], dispensing, administration or monitoring). DOAC doses not adapted to renal function were considered as prescribing issues, unless clear evidence pointed to the initial DOAC dose being appropriate and that renal function was not properly monitored. In the latter case, the stage of medication process involved in medication error was monitoring. The contribution of serious ADRs to hospital admission was assessed according to definitions proposed by Hallas and colleagues [21] . All the tools were first pilottested on five clinical cases by three experienced clinical pharmacists (A.-L.S., O.D. and A.S.). Disagreements and imprecisions were highlighted so that the different tools were improved. Scales and definitions are presented in Appendix S2.
Statistical analysis
Due to the observational nature of the study, we did not calculate a minimum sample size. However, to have a good balance between the labour-intensive character of the qualitative part and the achievement of reliable quantitative results, we were willing to have at least 40 patients with a serious ADR in each group (DOAC and VKA) [22, 23] . We selected a 1:1 DOAC:VKA sample to explore to the same extent the factors contributing to DOAC-and VKA-related ADRs in the qualitative part of the study. Patient enrolment was therefore followed and temporarily stopped in one group if there were more patients included in this group. Outcome measurements were compared in a descriptive way between DOAC-and VKA-treated patients.
Factors contributing to preventable ADRs
For cases of serious and (potentially) preventable ADRs, we performed semi-structured interviews with the GPs of the patients to identify contributing factors to ADRs. This 'qualitative research' approach is frequently used in patient safety research to reach comprehensive understanding of an issue [24] . GPs were contacted by phone after patient discharge. They were informed about the voluntary nature of their participation and data confidentiality. Interviews were held at the practice site of GPs agreeing to participate. We used a guide with specific, open-ended questions that was pilot-tested with three GPs. The subjects covered were: difficulties encountered for prescribing and monitoring of oral anticoagulants, personal understanding of anticoagulantassociated adverse events (in general and for the patient included), and means of improvement of the use of oral anticoagulants. The interviews lasted between 30 and 45 min. Each participant provided informed consent.
Analysis of the interviews
Interviews were recorded and transcribed verbatim. Themes and categories were identified inductively by A.-L.S. and discussed with a second researcher (K.A.) until agreement was reached. Categorization was refined according to the framework for analysing risk and safety in clinical medicine [25] . The adopted coding frame was then applied to all transcripts, using the software QSR NVivo 10. We organized two focus groups of 90 min to present results of the analysis to different health care professionals (cardiologist, GP, pharmacist, geriatrician and haematologist) and patients. Participants were asked whether they agree or disagree with identified themes. A final report was drawn up accordingly, and checked by A.S.
Results
Study population
Eighty-nine patients admitted to the emergency department were included in the analysis (46 DOAC-and 43 VKA-treated patients), as presented in Figure 1 . Median age was 79 years. Fifty-four percent were male, and 79% were living at home. The most frequent comorbidities were atrial fibrillation (79%), hypertension (73%) and coronary artery disease (33%). On admission, 45% of the patients had impaired renal function. Seventy-six percent used at least five daily drugs. Sociodemographic, clinical and medication data are presented separately for DOAC and VKA in Table 1 .
Anticoagulation
Rivaroxaban was the most prescribed DOAC (n = 29), followed by apixaban (n = 9) and dabigatran etexilate (n = 8). VKA-treated patients were taking acenocoumarol (n = 40), phenprocoumone (n = 2) and warfarin (n = 1). The main indications of treatment were non-valvular atrial fibrillation (85% for DOAC, 56% for VKA) and secondary prevention of venous thromboembolism (15% for DOAC, 19% for VKA). Cardiologists initiated oral anticoagulants for 46% of the patients, while the GP first prescribed in 12% of the cases. Most patients had been treated for more than 1 year (60% and 78% for DOAC and VKA respectively), as shown in Table 1 . Only two DOAC-and three VKA-treated patients were within their first month of treatment. Twenty patients under DOAC had been taking VKA previously (43%). The main reasons for switching from VKA to DOAC included unstable INR results (n = 5), greater comfort (n = 4) and bleeding events (n = 2). One of the 20 patients was admitted to the ED within 30 days after drug transition.
Characteristics of adverse events
We observed 19 thromboembolic events (21%) and 70 bleeding events (79%). Characteristics of adverse events and management of bleeding are presented in Table 2 . Gastrointestinal bleedings were the most frequent adverse events (n = 34), followed by intracranial bleeding (n = 16). Twelve patients presented with a haemoglobin level ≤8 g dl À1 .
Concerning VKA-treated patients, the INR value (mean ± SD) on admission was 2.0 ± 0.7 for thromboembolic events (n = 9) and 3.6 ± 2.2 for bleeding events (n = 34). Thromboembolic events were recurrent in 12 of the 19 patients (63%), while 14 of the 70 patients with bleeding (20%) already had a previous episode of major bleeding. Among the 32 patients with gastrointestinal bleeding events, 12 (7 DOAC, 5 VKA) were taking proton pump inhibitors concomitantly (38%).
Analysis of anticoagulant prescribing
Analyses of DOAC and VKA prescriptions according to the Medication Appropriateness Index (MAI) are presented in Table 3 . Inappropriate ratings concerning drug-drug interactions were frequent, both for DOACs and VKAs. 
Assessment of adverse events
For the 46 patients taking DOAC, 38 adverse events were evaluated as serious ADRs. Among these, 20 ADRs (53%) were considered to be (potentially) preventable. Prescribing was the main stage of medication process involved in medication error (n = 16), followed by compliance (n = 5). Concerning the 43 VKA-treated patients, 41 adverse events were evaluated as
Figure 1
Flow chart of the inclusion processDOAC: direct oral anticoagulant, LMWH: low molecular weight heparin, VKA: vitamin K antagonist.
Preventability of oral anticoagulant-associated adverse drug reactions serious ADRs. Twenty-five of these ADRs (61%) were (potentially) preventable. For VKAs, monitoring (n = 16) and prescribing (n = 14) were the main stages of medication process involved in medication errors. Details on the assessment of adverse events (causality, seriousness and preventability) are presented in Table 4 , while Table 5 shows some 
Factors contributing to preventable ADRs
Twenty-one GPs were interviewed (9 female, 12 male). Nine participants had more than 30 years of experience in general medicine, while five had been practising for less than 10 years. Factors contributing to preventable ADRs were classified into five main categories: the patient, the health care professional (HCP), the task, communication and the work environment. Categories and subcategories are described below, and illustrative verbatim quotes are presented in Table 6 .
The patient. Patient non-adherence was frequently reported for both DOACs and VKAs, as a result of carelessness, forgetfulness or lack of understanding. Some patients did not take their treatment deliberately, because they were scared of or experienced side effects. GPs mentioned the poor drug management of community-dwelling older patients. For VKAs, adherence issues also applied to therapeutic monitoring. One participant related the case of a DOAC patient for whom non-adherence remained undetected and led to an adverse event.
Patient characteristics were perceived to contribute to ADRs, such as falls, cognitive disorders or acute infections. The main concern for DOAC patients was about renal failure, especially in the frail elderly. Patients often did not think of reporting an adverse event or the intake of an over-thecounter medication to their GP.
The health care professional. Some GPs felt uncomfortable with DOAC therapy, because of a lack of knowledge. GPs appeared not to question cardiologists' recommendations with regard to anticoagulation, considering that specialists do not make mistakes. The same was true for the reassessment of aspirin prescription. The lack of awareness of anticoagulation risks among nursing home staff was also highlighted.
Table 4
Assessment of causality, seriousness and preventability of anticoagulant-related adverse events by four independent reviewers using pilot-tested scales Opinions differed about GPs' knowledge of their DOACtreated patients. Two GPs estimated that they provide them with poorer quality care compared to VKA-treated patients, because of a lack of familiarity. Medical history of patients who have changed family physician seemed to be frequently incomplete, preventing treatment review.
The task. Two main tasks were addressed during the interviews: prescribing and patient monitoring. GPs seemed to prescribe only one drug among each class of oral anticoagulants, with which they are more familiar. Initiation of VKA therapy remained highly intuitive, possibly leading to overdose. Some participants acknowledged that they did not think about reassessing long-term prescribed VKA.
Drug-drug interactions were perceived as a risk factor for ADRs, both for DOAC and VKA. The addition of new medications by several HCP without control of interactions was highlighted. Some GPs prescribed NSAIDs deliberately, in the absence of alternative. GPs considered the community pharmacist as a key player in avoiding the dispensation of medications interacting with oral anticoagulants.
In terms of monitoring, management of out-of-range INR values was found to be complicated in primary care. VKA dose adjustments seemed to be based on physician experience. GPs considered that there was no specific follow-up for DOAC patients, with the exception of renal function monitoring. However, DOAC dose was not always adapted in case of moderate renal impairment. The higher risk of unnoticed adverse events was highlighted for DOACs, because of the lack of regular visits. Perioperative management of DOACs and VKAs was seen as a high-risk period for medication errors, as illustrated by several GPs.
Communication. Communication issues with secondary care were discussed by half of the GPs, such as the lack of accessibility of hospital physicians. Poor information transfer at hospital discharge was frequently reported, including incorrect hospitalization reports or the lack of explanation concerning VKA treatment modalities (e.g. history of INR values, resumption). GPs regretted that anticoagulant therapy was often modified during hospitalization without them being informed, resulting in complicated consultations when the patient returns home.
The communication of INR values in primary care was also at high risk. The example of an INR value misunderstood over the phone, leading to patient ADR, was among others reported. Patients seemed often to request prescriptions by telephone, preventing regular follow-up in DOAC patients.
Work environment. Workloads of GPs and specialists were both mentioned as causes of ADRs, preventing close monitoring, treatment review or adequate information sharing. The long timeframe to get results of INR measurements in primary care was also highlighted. Consultation cost seemed to play a role in monitoring nonadherence, even if the patient is later partly reimbursed. Concerning DOACs, the absence of dedicated consultations was perceived as a factor of low GP involvement in anticoagulant treatment.
The galenic formulation of acenocoumarol (i.e. small unscored tablets) was considered inappropriate to low-dose intake in elderly patients. Some GPs regretted that DOAC packages were for 3 months of treatment, preventing regular contact with the patient. Several GPs felt that the pharmaceutical industry conveyed a comforting image of DOACs. The banalization of anticoagulation may have led to decreased vigilance of patients and HCP. An 80-year-old man living in nursing home, under acenocoumarol for atrial fibrillation.
He was admitted for anaemia (Hb 6.7 g dl À1 ).
He had been suffering from melena for 4 months.
Potentially preventable
Monitoring
Melena had been present for several months but was not highlighted before ED admission.
ED: emergency department, GI: gastrointestinal, Hb: haemoglobin, INR: International normalized ratio, LMWH: low molecular weight heparin, NSAID: nonsteroidal anti-inflammatory drugs Table 6 Illustrative verbatim quotes from semi-structured interviews performed with general practitioners to identify contributing factors to oral anticoagulant-related adverse drug reactions
Category Illustrative verbatim quote
The patient Intentional non-adherence 'I sometimes have people on oral anticoagulants who experience hematuria. So you have people on two doses a day who only want to take one. With all the consequences … It seems that for 12 hours they are anticoagulated, and for 12 hours they are not.
' [GP4]
Unintentional non-adherence 'To come back to that patient who had been on Sintrom [acenocoumarol] and then moved on to DOAC, I didn't think of checking regularly with him whether he understood the usefulness of his drugs and whether he followed his treatment correctly. It took an acute episode to make me realize that the patient was no longer able to manage his medications.
' [GP7]
Complex condition 'With elderly people who don't drink very much, take diuretics, take an ACE inhibitor, and then have a fever and don't drink for three days, we are called after three days. When we monitor renal function, we get some serious surprises.
' [GP1]
The health care professional Drug knowledge 'I have some fears, because I don't have enough knowledge. There is a huge amount you need to learn about these anticoagulants. … So with those, I manage less, I manage less. Because I don't know enough about those products.' [GP17]
'And I had a serious problem two weeks ago. I was on duty on a Friday night. I was called at 12:30-1:00 am by a nursing home because an elderly person had fallen. So I asked the caregiver, "Are there any anticoagulants?" That's the first thing I ask. "Ah, I don't think so, I don't know. 
Discussion
In this study, more than half of both DOAC-and VKAassociated serious ADRs were deemed potentially preventable. Prescribing issues were frequent for DOACs, while monitoring was the main stage of medication process involved for VKAs. We identified other contributing factors to ADRs that were common to both classes of oral anticoagulants, such as pharmacodynamic drug interactions or communication.
Patient characteristics were similar to previous studies describing DOAC-associated bleeding events [26] . Older age and renal impairment are two risk factors for experiencing major bleeding events, as shown in a registry of rivaroxaban patients [27] . Polypharmacy, which was present in 76% of our patients, was previously reported to be a determinant of higher bleeding risk and preventable medication-related hospital admissions [28, 29] . Therefore, interventions to improve anticoagulation management should primarily focus on these 'high-risk' patients. Hypertension is an important reversible bleeding risk factor in patients taking oral anticoagulants [30] . Although it was a frequent comorbidity in our population, only one DOAC patient with intracranial bleeding had severe uncontrolled hypertension.
Patients were mainly taking rivaroxaban and acenocoumarol, in accordance with the anticoagulant prescribing pattern in Belgium. Nearly half of DOAC patients previously received VKA treatment, with similar proportions observed in pivotal trials and prospective registries [31, 32] . Patients seemed to be switched to the same extent because of labile INR or for convenience. In guidelines on atrial fibrillation, INR stability and patient preference were both emphasized when considering DOAC in patients already receiving VKA [30, 33] .
Our finding that gastrointestinal (GI) bleedings were the most frequent DOAC-related ADRs is consistent with Phase 3 and real-world trials [34, 35] . The higher rate of lower GI bleeding in DOAC compared to VKA patients was described in a multicentric observational study [36] . The presence of active anticoagulant substances in the gut of DOAC patients has emerged as a possible explanation [37] . Guidelines and expert opinions suggest gastro-protective agents in anticoagulated patients with a history of peptic ulcer or GI bleeding, as well as in patients taking antiplatelet drugs [38, 39] . In our patients admitted with GI bleeding, 40% of those who were not receiving gastro-protective agents had a history of peptic ulcer or were taking antiplatelet therapy.
To our knowledge, this is the first study to assess the preventability of DOAC-related ADRs. We used a mixedmethod design, combining a prospective cohort study and semi-structured interviews to get a better understanding of this patient safety issue. The analysis took into consideration initial or transition phases of anticoagulant therapy, as they were shown to entail a higher risk for bleeding or thromboembolic events [31, 40] . Previous studies reported high preventability rates for adverse events associated with the use of warfarin in outpatients (49%), or any anticoagulant in hospitalized patients (70%) [41, 42] . Given the fixed-dose regimen of DOACs, a lower rate of preventable ADRs could have been hypothesized. However, our results showed comparable preventability between DOACs and VKAs, with rates in the range of previous estimates. This observation may be explained by the fact that many causes of preventable ADRs apply to all oral anticoagulants, as revealed through interviews.
Inappropriate prescribing of DOACs was well described in previous observational studies [15, 18] . Several reports highlighted the occurrence of bleeding events in DOAC patients for whom both drug and dose selections were judged inadequate [43, 44] . In older patients, for instance, DOACs should be avoided in case of severe renal impairment, while a reduced dose is sometimes recommended for creatinine clearances below 50 ml min À1 [45] . Our results showed that choosing the most appropriate oral anticoagulant, tailored to patient characteristics, has become a new challenge for clinicians. Management of drug-drug interactions also remains difficult in DOAC patients. Combination therapy with aspirin represents a serious matter of concern, as it often has no indication and increases bleeding risk by 50% [46, 47] . Moreover, the frequent concomitant use of P-gp inhibitors (e.g. amiodarone, simvastatin) was associated with increased DOAC levels and bleeding risk [35, 48] . To improve DOAC prescribing, interventions combining education and informatics tools should be promoted [49] . The role of community pharmacist in detecting anticoagulant-related problems has also been demonstrated [50] . Patient-related factors were often quoted during the interviews, both for older and younger patients, emphasizing the need to reinforce the education of anticoagulated patients. In a European survey, less than a quarter of DOAC patients were aware of kidney function monitoring or that some medications had to be avoided [51] . Providing patients with repeated information and suitable education material should reduce misunderstanding or underreporting of adverse events. Another area for improvement relates to DOAC management in nursing homes. Adverse events associated with the use of warfarin were previously demonstrated to be common in this setting, and often preventable [52] . We observed a limited awareness of nursing home staff about DOACs, which should be addressed.
Our findings suggested that clinical follow-up of DOAC patients was neglected compared to VKA patients, due to the lack of regular therapeutic monitoring. Consultations entirely dedicated to DOAC management should be planned at least every 3 months, including assessment of compliance, side effects and drug interactions [38, 53] . This specific follow-up can be performed by GPs, provided that they receive appropriate training [54] . Patients may also benefit from follow-up care in dedicated anticoagulation clinics. However, this should be carried out in close collaboration with the GP.
In this study, communication was an important contributing factor to ADRs regardless of the class of oral anticoagulants. We observed poor communication between healthcare providers, or between patients and healthcare providers. A previous root-cause analysis showed that communication was the second cause of adverse events in patients taking warfarin [55] . Especially, transitions of care are critical periods for the occurrence of medication errors. The low availability of discharge reports and lack of direct communication were previously characterized [56] . This issue takes on greater significance with high-risk medications like oral anticoagulants.
Clinical outcomes were consistent with previous findings. Two multi-centre cohort studies reported a lower 30-day mortality with DOACs compared to VKAs, after major bleeding and in the absence of specific DOAC reversal agents [36, 57] . However, in the present study, thromboembolic events were also considered and sample size was small.
Idarucizumab was used for one patient taking dabigatran, who experienced major bleeding. We were not allowed to evaluate the cases of eight patients who died before inclusion in the study. Mortality data have therefore been underestimated.
Our study presents several limitations. First, patients already discharged home at the time of identification were not included. However, these ADRs were not expected to be serious. Second, our study did not consider ADRs associated with the underuse of oral anticoagulants (i.e. thromboembolic events occurring while anticoagulation was indicated but not prescribed). Finally, only clinical pharmacists and haematologists participated in the assessment of adverse events. Conversely, only GPs' opinions were explored during the interviews. We did not calculate the inter-rater reliability of scales, but all tools were pilot-tested and improved accordingly.
In conclusion, ADRs related to the use of oral anticoagulants are still largely preventable despite the use of DOACs. Interventions focusing on prescribing, patient education and continuity of care should be designed to help improve DOAC management in clinical practice.
